This content is for healthcare professionals only. Please confirm that you are a healthcare professional.AcceptDecline
touchCONGRESS Expert Interviews: Advanced Breast Cancer
Length of activity: 70 minutes Prof. Gabriel Hortobagyi, Prof. Joan Albanell, Prof. Sibylle Loibl, Prof. Mario Campone, Prof. Giuseppe Curigliano, and Prof. Stephen Johnston discuss the latest data from the (ESMO) Breast Cancer Congress 2019, and consider what the findings may mean for global and regional clinical practice.
THIS CONTENT IS AVAILABLE FOR FREE TO REGISTERED USERS You are not currently logged in. LOGIN or REGISTER to access this content
LOGIN or REGISTER to access this content
Immediate, and unrestricted free access to all resources
Earn AMA PRA Category 1 Credits™ for completing accredited activities
Bi-weekly scientific newsletters highlighting the latest emerging data and industry news
Access to your personalised learning profile and CME record.
Watch a series of internationally renowned clinical specialists from Europe and the United States discuss key clinical data of interest from the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, United States, 31 May–4 June 2019.
The potential implications of these data for optimizing clinical outcomes for patients with advanced breast cancer are explored from both global and regional perspectives.
The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer
After watching these touchCONGRESS Expert Interviews from ASCO 2019, you should be able to:
Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
Please feedback on this touchCONGRESS Expert Interviews on the following: (scale 1–5, 1 strongly disagree; 5 strongly agree).